search
Back to results

The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)

Primary Purpose

Pregnancy, Depression

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Omega-3 polyunsaturated fatty acids
Olive oil
Sponsored by
Tokyo Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy focused on measuring Pregnancy, Depression, omega-3 fatty acids

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. pregnant women aged 20 years or older
  2. between 12-24 weeks gestation
  3. a Japanese conversational ability in Japan site or a Mandarin conversational ability in Taiwan site to understand the scope of the present trial and to provide written consent for study participation
  4. planned to take assessments after childbirth
  5. an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more
  6. to have good physical health judged by obstetricians.

Exclusion Criteria:

  1. history and current suspicion of psychosis or bipolar I disorder or substance-related disorder or eating disorder or personality disorder
  2. Serious psychiatric symptoms such as self-harm behavior or in need of rapid psychiatric treatment
  3. difficult to expect a normal birth (ex: fetal malformation etc.)
  4. having a history of bleeding disorder such as von Willebrand's Disease
  5. regular treatment with aspirin or warfarin within the last 3 months
  6. a smoking habit of ≥40 cigarettes per day
  7. regular treatment with ethyl icosapentate or regular consumption of omega-3 PUFA supplements within the last 3 months
  8. a habit of eating fish as a main dish ≥4 times per week.

Sites / Locations

  • Toda Chuo Women's Hospital
  • National Center for Child Health and Development
  • Tokyo Medical University
  • China Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Omega-3 polyunsaturated fatty acids

olive oil

Arm Description

1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily

2880mg olive oil daily

Outcomes

Primary Outcome Measures

total score of the Hamilton Rating Scale for Depression (HAMD)

Secondary Outcome Measures

total score of HAMD
major depressive disorder (MDD) as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)
total scores on the Edinburgh Postnatal Depression Scale (EPDS)
total score of the Beck Depression Inventory Ⅱ(BDI-Ⅱ)
omega-3 fatty acids concentrations in erythrocytes
brain-derived neurotrophic factor (BDNF) in serum
estrogen in plasma
oxytocin in plasma
progesterone in plasma
human chorionic gonadotropin (hCG) in plasma
phospholipase A2 in plasma

Full Information

First Posted
June 15, 2014
Last Updated
December 19, 2017
Sponsor
Tokyo Medical University
Collaborators
China Medical University, Taiwan, Japan Society for the Promotion of Science (JSPS), University of Toyama, Chiba University, National Center for Child Health and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT02166424
Brief Title
The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)
Official Title
The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tokyo Medical University
Collaborators
China Medical University, Taiwan, Japan Society for the Promotion of Science (JSPS), University of Toyama, Chiba University, National Center for Child Health and Development

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty acids for pregnant women with depressive symptoms.
Detailed Description
Maternal depression can have a significant harmful influence on both mothers and children. Considering the possibility of adverse effects of antidepressants and previous meta-analyses showing the positive effects of omega-3 polyunsaturated fatty acids (PUFAs) supplementation in reducing depressive symptoms, omega-3 PUFAs may provide a safe strategy. The investigators evaluate efficacy and safety of omega-3 PUFAs for pregnant women with depressive symptoms. (Participants who skipped taking supplements for more than 7 days will be excluded from a per protocol analysis.)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Depression
Keywords
Pregnancy, Depression, omega-3 fatty acids

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
108 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Omega-3 polyunsaturated fatty acids
Arm Type
Active Comparator
Arm Description
1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
Arm Title
olive oil
Arm Type
Placebo Comparator
Arm Description
2880mg olive oil daily
Intervention Type
Dietary Supplement
Intervention Name(s)
Omega-3 polyunsaturated fatty acids
Other Intervention Name(s)
1200mg EPA and 600mg DHA daily
Intervention Type
Dietary Supplement
Intervention Name(s)
Olive oil
Other Intervention Name(s)
2880mg olive oil daily
Primary Outcome Measure Information:
Title
total score of the Hamilton Rating Scale for Depression (HAMD)
Time Frame
Twelve weeks
Secondary Outcome Measure Information:
Title
total score of HAMD
Time Frame
4-6 weeks after childbirth
Title
major depressive disorder (MDD) as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)
Time Frame
Twelve weeks, 4-6 weeks after childbirth
Title
total scores on the Edinburgh Postnatal Depression Scale (EPDS)
Time Frame
Twelve weeks, 4-6 weeks after childbirth
Title
total score of the Beck Depression Inventory Ⅱ(BDI-Ⅱ)
Time Frame
Twelve weeks, 4-6 weeks after childbirth
Title
omega-3 fatty acids concentrations in erythrocytes
Time Frame
Tweve weeks, 4-6 weeks after childbirth
Title
brain-derived neurotrophic factor (BDNF) in serum
Time Frame
Twelve weeks, 4-6 weeks after childbirth
Title
estrogen in plasma
Time Frame
twelve weeks, 4-6 weeks after childbirth
Title
oxytocin in plasma
Time Frame
twelve weeks, 4-6 weeks after childbirth
Title
progesterone in plasma
Time Frame
twelve weeks, 4-6 weeks after childbirth
Title
human chorionic gonadotropin (hCG) in plasma
Time Frame
twelve weeks, 4-6 weeks after childbirth
Title
phospholipase A2 in plasma
Time Frame
twelve weeks, 4-6 weeks after childbirth
Other Pre-specified Outcome Measures:
Title
gestational age
Time Frame
at childbirth
Title
gestational diabetes mellitus
Time Frame
4-6 weeks after childbirth
Title
gestational hypertension or preeclampsia
Time Frame
4-6 weeks after childbirth
Title
induced labour
Time Frame
at childbirth
Title
estimated blood loss
Time Frame
at childbirth
Title
cesarean section
Time Frame
at childbirth
Title
operative vaginal delivery
Time Frame
at childbirth
Title
birthweight
Time Frame
at childbirth
Title
one minute apger
Time Frame
4-6 weeks after childbirth
Title
5-minute apgar
Time Frame
4-6 weeks after childbirth
Title
neonatal intensive care unit admission
Time Frame
4-6 weeks after childbirth
Title
cholesterol
Time Frame
twelve weeks and 4-6 weeks after childbirth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: pregnant women aged 20 years or older between 12-24 weeks gestation a Japanese conversational ability in Japan site or a Mandarin conversational ability in Taiwan site to understand the scope of the present trial and to provide written consent for study participation planned to take assessments after childbirth an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more to have good physical health judged by obstetricians. Exclusion Criteria: history and current suspicion of psychosis or bipolar I disorder or substance-related disorder or eating disorder or personality disorder Serious psychiatric symptoms such as self-harm behavior or in need of rapid psychiatric treatment difficult to expect a normal birth (ex: fetal malformation etc.) having a history of bleeding disorder such as von Willebrand's Disease regular treatment with aspirin or warfarin within the last 3 months a smoking habit of ≥40 cigarettes per day regular treatment with ethyl icosapentate or regular consumption of omega-3 PUFA supplements within the last 3 months a habit of eating fish as a main dish ≥4 times per week.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daisuke Nishi, M.D., Ph.D.
Organizational Affiliation
Tokyo Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kuan-Pin Su, M.D., Ph.D.
Organizational Affiliation
China Medical Univeristy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Toda Chuo Women's Hospital
City
Toda
State/Province
Saitama
ZIP/Postal Code
335-0022
Country
Japan
Facility Name
National Center for Child Health and Development
City
Setagaya
State/Province
Tokyo
Country
Japan
Facility Name
Tokyo Medical University
City
Shinjyuku-ku
State/Province
Tokyo
ZIP/Postal Code
160-8402
Country
Japan
Facility Name
China Medical University
City
Taichung
Country
Taiwan

12. IPD Sharing Statement

Citations:
PubMed Identifier
27630014
Citation
Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka YJ. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. BMC Psychiatry. 2016 Sep 15;16(1):321. doi: 10.1186/s12888-016-1031-2.
Results Reference
derived

Learn more about this trial

The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)

We'll reach out to this number within 24 hrs